Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 13, 2025

Applied Materials Announces Fourth Quarter and Fiscal Year 2025 Results

View original at globenewswire.com
Applied Materials Announces Fourth Quarter and Fiscal Year 2025 Results Record annual revenue $28.37 billion, up 4 percent year over yearRecord annual GAAP EPS $8.66 and record non-GAAP EPS $9.42, up 1 percent and 9 percent year over year, respectivelyQuarterly revenue $6.80 billion, down 3 percent year over yearQuarte…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Applied Materials delivered its sixth consecutive year of growth in fiscal 2025

    80% confidence

  • Higher demand expected to begin in the second half of calendar 2026

    80% confidence

  • AI adoption drives substantial investment in advanced semiconductors and wafer fab equipment

    80% confidence

  • Applied Materials is well positioned at the highest value technology inflections in the fastest growing areas of the market

    80% confidence

  • R&D investments targeted to create products enabling faster and more energy-efficient transistors, chips and systems

    80% confidence

Data points we hold from this source

Applied Materials, Inc. · cash7241 million_USD
Applied Materials, Inc. · debt6555 million_USD
Applied Materials, Inc. · gross margin48.0 percent
Applied Materials, Inc. · revenue us655 million_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com
Applied Materials Announces Fourth Quarter and Fiscal Year 2025 Results — Source | Via News | Finance Via News